Journal article
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Blood, Vol.141(6), pp.567-578
02/09/2023
DOI: 10.1182/blood.2022017865
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC’s inaugural meetings are presented herein.
Details
- Title: Subtitle
- North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
- Creators
- Naveen Pemmaraju - The University of Texas MD Anderson Cancer CenterHagop Kantarjian - The University of Texas MD Anderson Cancer CenterKendra Sweet - Moffitt Cancer CenterEunice Wang - Roswell Park Cancer InstituteJayastu Senapati - The University of Texas MD Anderson Cancer CenterNathaniel R. Wilson - The University of Texas Health Science Center at HoustonMarina Konopleva - The University of Texas MD Anderson Cancer CenterArthur E. Frankel - West Palm Beach VA Medical CenterVikas Gupta - Princess Margaret Cancer CentreRuben Mesa - The University of Texas Health Science Center at San AntonioMatthew Ulrickson - Banner MD Anderson Cancer Center, Gilbert, Arizona, United States.Edward Gorak - New England Baptist HospitalSumeet Bhatia - Community Health NetworkTulin Budak-Alpdogan - Cooper University HospitalJames Mason - Scripps ClinicMaria Teresa Garcia-RomeroNorma Lopez-Santiago - National Pediatrics Institute, Mexico City, Mexico.Gabriela Cesarman-Maus - Instituto Nacional de CancerologíaPankit Vachhani - University of Alabama at BirminghamSangmin Lee - Weill Cornell MedicineVijaya Raj Bhatt - University of Nebraska Medical CenterWilliam Blum - Emory UniversityRoland B. Walter - Fred Hutch Cancer CenterDale Bixby - University of Michigan–Ann ArborIvana Gojo - Johns Hopkins UniversityMadeleine Duvic - The University of Texas MD Anderson Cancer CenterRaajit K. Rampal - Memorial Sloan Kettering Cancer CenterMarcos de Lima - University Hospitals Seidman Cancer CenterJames Foran - Mayo Clinic in FloridaAmir T. Fathi - Harvard UniversityAric Cameron Hall - University of Wisconsin–MadisonMeagan A. Jacoby - Washington University in St. LouisJeffrey Lancet - Moffitt Cancer CenterGabriel Mannis - Stanford UniversityAnthony S. Stein - City Of Hope National Medical CenterAlice Mims - The Ohio State UniversityDavid Rizzieri - Novant HealthRebecca Olin - University of California, San FranciscoAlexander Perl - University of PennsylvaniaGary Schiller - University of California, Los AngelesPaul Shami - Huntsman Cancer InstituteRichard M. Stone - Dana-Farber Cancer InstituteStephen Strickland - Sarah CannonMatthew J. Wieduwilt - University of California, San DiegoNaval Daver - The University of Texas MD Anderson Cancer CenterFarhad Ravandi - The University of Texas MD Anderson Cancer CenterSumithira Vasu - The Ohio State UniversityMonica Guzman - Cornell UniversityGail J. Roboz - Cornell UniversityJoseph Khoury - The University of Texas MD Anderson Cancer CenterMuzaffar Qazilbash - The University of Texas MD Anderson Cancer CenterPhyu P. Aung - The University of Texas MD Anderson Cancer CenterBranko Cuglievan - The University of Texas MD Anderson Cancer CenterYazan Madanat - Southwestern Medical CenterMohamed A. Kharfan-Dabaja - Mayo Clinic in FloridaAnna Pawlowska - City Of Hope National Medical CenterJustin Taylor - University of MiamiMartin Tallman - Memorial Sloan Kettering Cancer CenterPrajwal Dhakal - University of IowaAndrew A. Lane - Dana-Farber Cancer Institute
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.141(6), pp.567-578
- Publisher
- Elsevier Inc
- DOI
- 10.1182/blood.2022017865
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Electronic publication date
- 11/18/2022
- Date published
- 02/09/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359763102771
Metrics
7 Record Views